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Available online 28 May 2013Abstract We report transplanted hemopoietic stem cells (HSC) preferentially lodge within two cells of mature megakaryocytes
(MM). With both populations comprising ~0.2% of bone marrow cells, this strongly suggests a key functional interaction. HSC
isolated from the endosteum (eLSKSLAM) showed significantly increased hemopoietic cell proliferation while in co-culture with
MM. Furthermore, eLSKSLAM progeny retained HSC potential, maintaining long-term multi-lineage reconstitution capacity in
lethally ablated recipients. Increased hemopoietic cell proliferation was not MM contact dependent and could be recapitulated
with media supplemented with two factors identified in MM-conditioned media: insulin-like growth factor binding protein-3
(IGFBP-3) and insulin-like growth factor-1 (IGF-1). We demonstrate that HSC express the receptor for IGF-1 and that IGF-1/IGFBP-3
induced increased hemopoietic cell proliferation can be blocked by an anti-IGF-1 neutralising antibody. However, co-cultures of
8N, 16N or 32N MMwith eLSKSLAM showed that MM of individual ploidy did not significantly increase hemopoietic cell proliferation.
Our data suggests that MM are an important component of the HSC niche and regulate hemopoietic cell proliferation through
cytokine release.
Crown Copyright © 2013 Published by Elsevier B.V. All rights reserved.Introduction
In adults, hemopoietic stem cells (HSC) reside in bone marrow
(BM),where theymaintain hemopoiesis. Schofield et al. initially
hypothesised that HSC reside in specific three-dimensional
structures from which they coined the term “niche” (Schofield,
1978). It is these niches that provide the extrinsic cues⁎ Corresponding author at: CSIRO, CMSE, Bag 10 Clayton South MDC,
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http://dx.doi.org/10.1016/j.scr.2013.05.007controlling HSC fate. The molecular and cellular compositions
of the HSC niche are under intense investigation and several
cell types have been shown to be important HSC regulators;
osteoblasts (OB), endothelial cells, CXCL-12 abundant reticular
cells, neuronal cells as well as Nestin+ mesenchymal stromal
cells (reviewed in Shen & Nilsson, 2012). These cells secrete
factors such as osteopontin, tenascin-C and hyaluronan which
influence HSC fate (Nilsson et al., 2003, 2005; Stier et al., 2005;
Grassinger et al., 2009; Ellis et al., 2011; Nakamura-Ishizu et
al., 2012).
Although mature megakaryocytes (MM) residing within BM
are primarily responsible for platelet production, they have
recently been shown to directly and indirectly influence the
BM microenvironment. Interleukin (IL)-6 released by MMlsevier B.V. All rights reserved.
783Megakaryocytes regulate hemopoietic stem cellsstimulates long-lived plasma cells (Winter et al., 2010) and
is also known as a HSC regulatory cytokine (Suzuki et al.,
1989; Jiang et al., 1994). Indirectly, MM influence HSC by
regulating OB, stimulating their proliferation and differen-
tiation while inhibiting osteoclast formation (Lemieux et al.,
2010; Ciovacco et al., 2010; Kacena et al., 2004, 2006; Bord
et al., 2005; Beeton et al., 2006). MM are also a major source
of factors such as thrombospondin, platelet-derived growth
factor and basic fibroblast growth factor-2, which are impor-
tant in the regulation and recovery of vasculature and
OB following BM damage (Kopp et al., 2006; Dominici et al.,
2009). In addition, MM endocytose cytokines such as insulin-
like growth factor (IGF)-1 and insulin-like growth factor
binding protein (IGFBP)-3 for later release (Chan & Spencer,
1998). There are two members within the family of IGFs
(IGF-1 and IGF-2) and six members within the IGFBP family
(IGFBP-1 to -6) (Martin & Baxter, 2011). Recently, IGF-2 and
IGFBP-2 secreted by foetal liver CD3+Ter119− cells and
tumorigenic cell lines were shown to increase HSC prolifer-
ation (Zhang & Lodish, 2004; Huynh et al., 2008, 2011). Due
to the many different ways in which MM can influence the BM
microenvironment, we investigated the role of MM in HSC
biology.Materials and methods
Mice
C57Bl/6 and PTPRCA congenic mice were purchased from
Monash University Animal Services (MAS, Monash University,
Australia). Red fluorescence protein (RFP) mice were bred at
MAS. All animals were used at age 6–8 wks and all experiments
were approved by Monash Animal Research Platform Ethics
Committee.Stem cell isolation
Murine hemopoietic stem cells were isolated as previously
described (Nilsson et al., 2005; Grassinger et al., 2010).
Briefly, iliac crests, femurs and tibias were excised, epi- and
metaphyseal regions removed and bone shafts flushed to
collect central (c) BM. Empty bones were pooled with epi-
and metaphyseal regions and crushed prior to collagenase I
and dispase II digestion for the isolation of endosteal (e) BM.
BM mononuclear cells, isolated by density centrifugation
(Nycoprep, Axis-Shield, Norway), were lineage-depleted based
on lineage-restricted marker expression (B220, Mac-1, Gr-1 and
Ter119) using Dynal beads (Life Technologies, USA). Lineage
negative (Lin−) cells were stained with anti-Sca-1-Pacific Blue
and anti-c-Kit-AF647 for hemopoietic progenitor cell isolation
(LSK: Lin−Sca-1+c-Kit+), and anti-CD150-PE and anti-CD48-FITC
for HSC isolation (LSKSLAM: Lin−Sca-1+c-Kit+CD150+CD48−).
Unless otherwise specified, all antibodies used in this project
were from BD Biosciences or Biolegend (USA). Flow cytometry
work was performed at FlowCore (Monash University) using
influx cell sorters or LSRII analysers (BD Biosciences). FACS
analysis was performed using Flow Jo software (Tree Star Inc.,
USA). Cell countswere performed on Sysmex KX-21N automated
cell counter (Sysmex, Japan).Megakaryocyte isolation
Megakaryocytes were isolated as recently described
(Heazlewood et al., 2013). Briefly, central marrow was
collected and depleted for lineage expressing cells (B220,
Mac-1 and Gr-1) prior to staining with anti-CD41-FITC.
Hoechst33342 (Life Technologies, USA) was used at 10 μM to
identify MM of different ploidy. MM were isolated as side
scatter (SSC)high, CD41bright cells through a 100 μm nozzle at
~5000 cells/s and 20 psi. Due to both cell size and high CD41
expression, logarithmic scales were used with a decreased
FITC voltage setting.
Cell culture
One hundred LSKSLAM cells and 100 MM were cultured in
100 μl of Iscove's Modified Dulbecco's media (IMDM, Life
Technologies) supplemented with 1% bovine serum albu-
min (BSA) (Sigma-Aldrich, USA) and recombinant human
insulin (10 μg/ml, Novartis, Switzerland), human transfer-
rin (100 μg/ml, Roche, USA), human low density lipopro-
tein (3 μg/ml, MP Biomedicals, Australia), L-glutamine
(2 mM/ml, Life Technologies), human IL-11 (100 ng/ml,
Chemicon, Australia), mouse stem cell factor (10 ng/ml,
Chemicon), human IL-6 (10 ng/ml, Peprotech, USA), human
FLT-3 ligand (10 ng/ml, Apollo Cytokine Research, Australia),
mouse IL-3 (133 U/ml, Immunex Corporation, USA), human
thrombopoietin (TPO) (5 ng/ml, Apollo Cytokine Research),
with or without mouse IGFBP-3 (775-B3), mouse IGF-1
(791-MG) or anti-mouse IGF-1 neutralising antibody (AF791)
(R&D Systems, USA). After 6–7 days of incubation at 37 °C
in an 85% nitrogen, 10% carbon dioxide and 5% oxygen hu-
midified incubator, cells were counted and stained with anti-
CD3-Pacific Blue, anti-B220-Pacific Blue, anti-B220-FITC,
anti-Gr-1-FITC and anti-Mac-1-FITC. MM-conditioned media
(CM)was collected fromwells containing prospectively isolated
MM cultured alone in the above media. “Aged media” was
media collected after 6–7 days in culture without MM.
Cytokine array
Analysis using a custom mouse cytokine array (RayBiotech,
USA) was performed following the manufacturer's specifica-
tions except for being adapted for analysis using the Li-Cor
Odyssey Infra-Red Imaging System (Li-Cor Biosciences, USA).
Briefly, membranes were blocked in Odyssey blocking buffer
supplemented with 0.05% Tween-20 before incubation in
control media or MM-CM, followed by biotin-conjugated
antibody before incubation with IRDyeTM 800CW-streptavidin
and visualization.
BM fluid collection
BM fluid from central BM was collected by flushing femurs
using 200 μl of 50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM
EDTA with 1× complete protease inhibitor cocktail (Roche,
Germany), 0.001 M PMSF and 0.001 M Na3VO4 (BM flush).
Empty femurs were crushed in 400 μl of the same buffer and
BM fluid collected (BM crush). BM fluids were centrifuged at
400 g for 5 min and used fresh for ELISA analysis.
784 S.Y. Heazlewood et al.Analysis of IGFBP-3 secretion
IGFBP-3 secretion was assessed by ELISA using a custom
mouse IGFBP-3 ELISA kit (RayBiotech). Diluted kit standard,
control media or MM-CM was incubated in 96-well plate
strips and labelled for detection at 450 nm using an EnSpire
2300 Multilabel Reader (Perkin Elmer, USA). The CM from
2000 prospectively isolated MM was assayed. It should be
noted that culture medium, and hence CM, was generated
using Sigma BSA, which, unlike a number of other BSA sources,
does not contain IGFBP-3 fragments (Twigg et al., 2000).Homing and spatial distribution assay
The homing and spatial distribution of central/endosteal
LSKSLAM cells was assessed as previously described (Grassinger
et al., 2010). Briefly, cells were stained with 0.5 μM carboxy-
fluorescein diacetate succinimidyl ester (CFD-A/CFSE, Life
Technologies) or 1 μM seminaphthorhodafluors-1 carboxylic
acid acetate succinimidyl ester (SNARF-1, Life Technologies),
pooled together with 2 × 105 whole BM filler cells from C57Bl/6
mice and transplanted intra-venously into non-ablated re-
cipients. SNARF and CFSE were used interchangeably on the
different populations in different experiments to negate any
possible effect seen due to the dyes themselves. Fifteen hours
post-transplant, BM from one iliac crest, femur and tibia was
analysed on a LSRII to determine the homing potential of
transplanted (CFSE+ versus SNARF-1+) cells. Total BM homing
was calculated based on the assumption that one iliac crest,
femur and tibia accounts for 15% of total BM (Smith & Clayton,
1970). The other set of leg bones were perfusion-fixed with 4%
paraformaldehyde/0.1% gluteraldehyde at physiological pres-
sure, excised, decalcified with 10% EDTA and embedded in
paraffin. Three micron serial sections were cut, de-waxed and
mounted in Vectashield fluorescence mount media (Vector
Laboratories, USA) before alternate sections were scored using
a fluorescence microscope with a UV/FITC/Texas Red triple
dichroic filter to allow for the simultaneous visualization of
CFSE+ (green) and SNARF-1+ (red) cells.Long-term reconstitution assay
Limiting dilution analysis of donor cells was used to measure
the frequency of cells that possess long-term multi-lineage
reconstitution potential (Grassinger et al., 2010). Lethally
irradiated recipients (split dose of 5 Gy each, 4 h apart)
were intra-venously transplanted with the progeny of 3, 10,
30 or 100 eLSKSLAM either cultured alone, or co-cultured
with MM. Cultured cells were pooled with 2 × 105 irradiated
(15 Gy) whole BM filler cells from C57Bl/6 mice for injection.
Hemopoietic reconstitution was assessed by lineage analysis of
the peripheral blood (PB) at 6, 12 and 20 wks post-transplant
with the addition of BM at 20 wks post-transplant. Following
red blood cell lysis, PB was stained with anti-CD3-Pacific Blue,
anti-B220-Pacific Blue, anti-B220-APC, anti-GR-1-APC and anti-
MAC-1-APC for flow cytometry analysis. Mice with a greater
than 1% donor reconstitution and B-cell, T-cell and myeloid
cell lineages were identified as having been transplanted with
HSC with long-termmulti-lineage reconstitution potential. The
frequency of long-term repopulating cells in each donor cellpopulation was calculated using L-Calc Software (Stem Cell
Technologies, Canada).
Real-time PCR
RNA was extracted from cells using Trizol (Life Technologies)
and DNase-treated with TURBO DNA-free Kit (Ambion, USA)
before reverse transcription with SuperScript III (Life
Technologies) as per the manufacturer's instructions, using
100 ng of RNA. All pre-formulated TaqMan gene expression
assays (containing unlabeled PCR primers and FAM dye-
labelled TaqMan MGB probe) were purchased from Applied
Biosystems (USA). Real-time PCR was performed using a 7500
Real Time PCR System (Applied Biosystems) using TaqMan
Universal PCR mix (Applied Biosystems) with mouse β-actin
as the endogenous control.
Identification of growth factor receptors on
stem cells
Anti-IGF-1R antibody was purchased from Abcam (ab32823,
UK) and anti-EGFR antibody was purchased from R&D (HXO01,
USA). Stem cells were sorted as above, stained with 10 μg/ml
of primary antibody or appropriate IgG control (BD Biosciences
or R&D) before visualization with 2 μg/ml of anti-AF488
secondary antibody (Life Technologies) via flow cytometry.
Immunohistochemistry
Perfusion fixed murine femoral sections were stained with
anti-mouse antibodies for anti-c-Mpl (the receptor for TPO)
(1 mg/ml, clone N-20, R&D, USA), anti-IGFBP-3 (5 μg/ml,
Clone 138202, R&D) or appropriate IgG isotype control (BD
Biosciences or R&D). To enhance the signal, staining was
amplified using a tyramide signal amplification fluorescence
system kit as per the manufacturer's instructions (Perkin
Elmer). Briefly, primary antibodies were detected with
1 μg/ml of biotinylated secondary antibody, then subse-
quently stained with SAV-HRP followed by FITC-conjugated
tyramide for 6 min at RT. Sections were counter-stained
with 4,6-diamidino-2-phenylindole (DAPI, Life Technologies)
before been mounted in Vectashield fluorescence mounting
media. MM were scored as endosteal if within the epi- or
metaphyseal regions of the bone or less than 12 BM cell
diameters from the bone:BM interface. This distance was
arbitrarily defined based on the furthest distance of cells of
donor origin 6 months post-transplant in non-ablated recip-
ients (Ellis et al., 2011; Grassinger et al., 2010; Nilsson
et al., 1997; Haylock et al., 2007).
Microscopy
Fluorescent cell cultures were visualized with an Olympus
IX71 microscope and images were acquired with an Olympus
U-CMAD3 camera. Fluorescently stained BM sections were
visualized using an Olympus BX51 microscope and images
were captured using an Olympus DP70 camera. A subset of
images was acquired using a DotSlide microscope (Olympus,
Germany). Light microscopy was performed on either a BX41
or CKX41 microscope (Olympus, Japan).
785Megakaryocytes regulate hemopoietic stem cellsStatistical analysis
Differences between sample groups were evaluated by
Mann–Whitney or one-way analysis of variance tests where
appropriate using GraphPad Prism (GraphPad Software, USA)
or SigmaPlot (Systat Software, USA). Data is presented as the
mean ± SEM.Results
MM are randomly distributed and transplanted HSC
preferentially lodge within two cells of MM
Analysis of the distribution of large, polyploid MM identified
using an anti-c-Mpl antibody and DAPI, revealed that 40.9 ±
0.4% of MM were within the endosteal region of C57Bl/6 BM
(Figs. 1A, B). MM were counted based on size and morphology;
c-Mpl stained green cells with a distinct and single nucleus,
larger than three BM cell diameters were counted as MM. Based
on our previous finding that 35.5 ±1.8% of extravascular BM cells
are contained within the metaphyseal region of murine long
bones (Ellis et al., 2011), plus taking into account the endosteal
BM cells within 12 cell diameter of bone along the diaphysis, this
represents a randomMMdistribution. However, analysis of stem
and progenitor cell homing following transplant demonstrated aA
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Figure 1 MM are randomly distributed and HSC preferentially lod
section of a C57Bl/6 femur stained with anti-c-Mpl (green) and DAPI (
polyploidy MM. All cells within the trabaculae rich regions of the epi-
of bone along the diaphyseal were classified as endosteal (individua
were scored per section. (C) Homed donor SNARF+ stem cell (red) in
lodged within two cells of MM (+MM) or more than two cells from M
cells were analysed per animal. (E) Proportion of donor LSKSLAM ce
from MM (−MM). Closed circles = LSKSLAM cells isolated from the e
central BM (p b 0.001) (n = 9, r = 3). In all graphs each symbol repres
data are the mean ± SEM.preferential lodgement near MM (Fig. 1C), with a significantly
higher proportion of transplanted LSKSLAM cells (76.5 ± 2.2%;
p b 0.0001) lodged within two cells of MM (Fig. 1D). Of these
cells, ~70% were LSKSLAM isolated from the endosteal region
and ~30% were LSKSLAM isolated from the central region
(Fig. 1E). Together with our previously published data showing
that LSKSLAM isolated from the endosteal region home more
readily to the BM compared to their central counterparts, and
endosteal LSKSLAM preferentially home back to the endosteal
region (Grassinger et al., 2009), we deduce that endosteally
isolated stem cells preferentially lodge near endosteal MM. The
odds ratio, a mathematical measure of association, between
MM (comprising ~0.2% of BM) and HSC (LSKSLAM comprising
~0.002% of BM (Grassinger et al., 2010)) co-localizing by chance
is 2000 to 1. This close association between MM and HSC in the
BM microenvironment suggests a possible functional interac-
tion. To investigate the interaction between HSC and MM in
vitro, we initially optimised a strategy for the prospective
isolation of viable MM.
Viable MM can be isolated by FACS using CD41 and
Hoechst33342
CD41, also known as glycoprotein (gp) IIb or integrin αIIb
chain, associates with CD61 (gpIIIa or integrin β3 chain) to
form the gpIIb/IIIa (CD41/CD61) complex expressed onC
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ge within two cells of MM 15 h post-transplant. (A) Longitudinal
blue). (B) Megakaryocyte distribution based on analysis of c-Mpl+
and metaphyseal femoral regions, as well as cells within 12 cells
l replicates (n) = 15, biological repeats (r) = 6). At least 200 MM
direct contact with MM. (D) Proportion of donor LSKSLAM cells
M (−MM) (p b 0.0001) (n = 9, r = 3). Approximately 30 LSKSLAM
lls lodged within two cells of MM (+MM) or more than two cells
ndosteal BM region, open circles = LSKSLAM cells isolated from
ents an individual animal and each colour a biological repeat. All
786 S.Y. Heazlewood et al.platelets, megakaryocytes, and early murine hemopoietic
progenitors (Jennings & Phillips, 1982; Ferkowicz et al.,
2003). MM can be isolated by FACS as SSChigh, CD41bright cells
(Figs. 2A, B) and sub-fractionated based on ploidy (Fig. 2C).
From a total of 49 sorts, an average of 1756 8N MM (12.6% of
total MM), 9109 16N MM (65.4% of total MM), 3035 32N MM
(21.8% of total MM) and 32 64N MM (0.2% of total MM) were
isolated from the femurs, tibias and iliac crests of a single
mouse. The purity and viability of isolated MM were confirmed
using microscopy, which revealed no contaminating cells, as
well as RT-PCR. As expected, the expression of tubulin-β1,
involved inmegakaryocytematuration, specifically pro-platelet
formation and platelet release, significantly increased as
megakaryocytes matured (Fig. 2D, p = 0.02). This confirmed
the purity of our sorted ploidy populations. All MM populations
tested showed constant minimal expression of Pu-1, a gene
known to be key in myeloid and B-lymphoid cell commitment
(data not shown).
Prospectively isolated megakaryocytes increase
hemopoietic cell proliferation in vitro
To determine if MM influence hemopoietic cell proliferation,
RFP+ MM were co-cultured with C57Bl/6 LSKSLAM cells
(Figs. 3A, B). While eLSKSLAM co-cultured with prospectively
isolated MM showed increased stem cell proliferation (Fig. 3C,
p b 0.0001), no significant difference was observed when HSC
isolated from the central BM (cLSKSLAM) were co-culturedC
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Figure 2 Isolation of viable MM using CD41 and Hoechst. (A) MM
image of isolated MM. (C) Using Hoechst33342, MM were sub-fractio
expression in MM of individual ploidy, relative to B-actin (n ≥ 3, p =with MM (Fig. 3D). Previously, we demonstrated that HSC
isolated from the endosteum have increased in vivo hemo-
poietic potential compared to their central counterparts
(Grassinger et al., 2010; Haylock et al., 2007) and as a
consequence, all further experimentation was conducted with
LSKSLAM isolated from the endosteal region. Analysis of HSC
progeny post-culture revealed no differences in the frequency
of lineage committed cells; however, a significant increase in
the absolute number of myeloid cells was detected (Figs. 3E,
F, p = 0.03). Perhaps surprisingly, co-culture of individual
ploidy MM with eLSKSLAM showed no significant increased
hemopoietic cell proliferation (Fig. 3G, p = 0.02). To deter-
mine the hemopoietic capacity of co-culture progeny, we
subsequently performed long-term limiting dilution transplant
analysis.
Cultured HSC retain reconstitution capacity and
multi-lineage potential
Limiting numbers of eLSKSLAM cells cultured for 6–7 days
with or without MM were transplanted into lethally ablated
recipients (Fig. 4A). Engraftment and multi-lineage recon-
stitution were measured in peripheral blood (PB) at 6 wks,
12 wks and 20 wks post-transplant, as well as in BM at 20 wks
post-transplant, with the relative proportion of T cells (CD3+),
B cells (B220+), myeloid cells (GR-1/Mac-1+) and other cells
assessed. While 1 in 26 starting eLSKSLAM cells cultured with
MM were capable of long-term, multi-lineage reconstitution,B
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Figure 3 Prospectively isolated megakaryocytes increase endosteal hemopoietic cell proliferation in vitro. (A) Sorting strategy for
the isolation of LSKSLAM cells. (B) RFP+ MM were co-cultured 6–7 days with C57Bl/6 LSKSLAM cells (image was taken with a 10×
objective). (C) Progeny of eLSKSLAM cultures with and without MM (p b 0.0001) (individual replicates (n) ≥ 36, biological repeats
(r) = 11). (D) Progeny of cLSKSLAM cultures with and without MM, compared to eLSKSLAM cells (p N 0.05) (n ≥ 11, r = 3). (E) Lineage
analysis of cells post-culture with or without MM. Myeloid = Gr-1+/Mac-1+, lymphoid = B220+/CD3+ (n = 6, r = 4). (F) Absolute
numbers of cells post-culture with or without MM. Myeloid = Gr-1+/Mac-1+, lymphoid = B220+/CD3+ (n = 6, r = 4, p = 0.026).
(G) eLSKSLAM co-cultured with MM of individual ploidy (p = 0.02) (n ≥ 12, r ≥ 4). In all graphs, each colour represents an
independent experiment; dots of the same colour represent replicates within the same experiment. All data is the mean ± SEM.
787Megakaryocytes regulate hemopoietic stem cellsonly 1 in 39 starting eLSKSLAM cells cultured alone possessed
the same potential (Fig. 4B). However, this difference in
frequencywas not significantly different. In experiments where
10 starting cell equivalents were transplanted; MM co-cultured
eLSKSLAM cells showed significantly increased long-term
multi-lineage reconstitution in lethally ablated mice (Fig. 4B,
p b 0.05). Therefore, co-culture with MM resulted in both the
expansion of cells withmulti-lineage reconstitution potential as
well as hemopoietic cell differentiation. This difference in
potential was only evident following the transplant of limiting
numbers of cells, allowing subtle differences in reconstituting
potential to be revealed. These findings are similar to those
previously reported for transplants into altered hemopoietic
microenvironments (Nilsson et al., 2005).
Both eLSKSLAM cultured alone or with MM demonstrated
long-term multi-lineage reconstitution of lethally ablated
recipients, with steady-state proportions of each cell typeevident at all time points after transplants of the progeny of
between 10 and 100 eLSKSLAM (Figs. 4C, D). These resultswere
equivalent to our previously published data showing lineage
commitment of transplanted eLSKSLAM cells (Grassinger et al.,
2010). Together, these findings demonstrate that MM signifi-
cantly increased the proliferation of lineage committed cell as
well as hemopoietic cells with reconstitution potential. Next,
we investigated the mechanism underpinning this MM stimu-
lated increase in proliferation.Megakaryocytes release IGF-1 and IGFBP-3 which
increase hemopoietic cell proliferation through the
IGF-1R
In order to determine if the observed increased proliferation
was contact-dependent, we cultured eLSKSLAM in MM-CM.
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788 S.Y. Heazlewood et al.No difference was detected in the proliferation of eLSKSLAM
in MM-CM compared to co-culture with MM, with a significant
increase in proliferation compared to cultured eLSKSLAM
alone (Fig. 5A, p b 0.001), demonstrating that increased
proliferation is not due to cell–cell interactions. A custom
cytokine array analysis highlighted multiple factors released
by MM (IGF-2 and IGFBP-2) which have previously been
shown to impact HSC proliferation in vitro (Zhang & Lodish,
2004; Huynh et al., 2008, 2011), as well as other IGF and
IGFBP family members (IGF-1 and IGFBP-3) (Fig. 5B).
qRT-PCR confirmed MM transcribe IGF-1 and IGFBP-3 mRNA
(Fig. 5C) and immunohistochemical analysis confirmed IGFBP-3
protein expression in situ (Fig. 5D). The presence of IGFBP-3 in
BM fluid as well as its release from prospectively isolated MM
into culture media was also evident immunohistochemically
and confirmed by ELISA (Figs. 5D, E, F). However, the fact that
IGFBP-3 transcript could only be detected in very high ploidy
MM, but equivalent protein was released from MM of otherploidy suggests that this factor is being endocytosed and
sequestered for later release, a process of cytokine storage
previously described for this cell type (Chan & Spencer, 1998).
Culture studies of eLSKSLAM in media supplemented with
IGFBP-3 alone, IGF-1 alone or IGF-1 and IGFBP-3 reproduced
the increased hemopoietic cell proliferation evident in HSC
cultures with MM, in an additive, IGFBP-3 dose dependent
manner (Fig. 5G, p b 0.001). Post-culture analysis showed
no difference in lineage commitment between eLSKSLAM
cells cultured alone or cultured with IGF-1 and IGFBP-3 (data
not shown). In addition, this IGF-1 and IGFBP-3 induced
hemopoietic cell proliferation could be inhibited by a
neutralising anti-IGF-1 antibody (Fig. 5H, p b 0.001). These
data suggest that IGFBP-3 is regulating HSC both indepen-
dently, as well as in conjunction with IGF-1. To elucidate the
mechanism by which IGF-1/IGFBP-3 regulates hemopoietic
cell proliferation, we examined HSC for two receptors to
which IGF-1 and potentially IGFBP-3 are known to bind: IGF-1
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790 S.Y. Heazlewood et al.receptor (IGF-1R) and epidermal growth factor receptor
(EGF-R) (Martin & Baxter, 2011; Mohseni-Zadeh & Binoux,
1997). HSC demonstrated high mRNA and protein expression
for IGF-1R but undetectable expression of EGF-R (Figs. 5I, J).
Together, the data suggests that IGF-1 and IGFBP-3 released
from MM act through the IGF-1R to mediate hemopoietic cell
proliferation.Discussion
We report that while MM are randomly distributed within
BM, 15-h post-transplant, HSC (LSKSLAM cells) preferentially
home to be within two cells of MM. To investigate whether
these two cell types could influence the biology of the other,
we refined a FACS based method for prospectively isolating
CD41+ MM, yielding a significant number of pure, viable 8N,
16N, 32N and 64N cells, allowing the assessment of MM and
HSC interactions in vitro. Sorted MM were intact and bright
under phase contrast pre- and post-culture. Previous methods
for isolating MM and their limitations are discussed in our
detailed chapter on the prospective isolation of viable MM
(Heazlewood et al., 2013). Our HSC/MM co-culture studies
showed that prospectively isolated MM significantly increased
the proliferation of hemopoietic cells, with an expansion of
cells with multi-lineage reconstitution potential as well as
differentiated hemopoietic cells. Our data also showed that
the MM stimulatory effect of hemopoietic cell proliferation is
not cell contact-dependent, but the proliferative stimulus is
mediated by the additive effect of released IGF-1 and
IGFBP-3, which can be inhibited by a neutralising anti-IGF-1
antibody. We also showed that HSC express IGF-1R.
While a recent review highlighted a number of papers
identifying IGFBP-3 as an inhibitor of proliferation (Martin &
Baxter, 2011), there are numerous studies implicating IGFBP-3,
both alone and in conjunction with IGF-1, in stimulating
cell proliferation. IGFBP-3 can stimulate cell proliferation by
activation of sphingosine kinase-1, leading to the production of
sphingosine-1-phosphate and transactivation of IGF-1R (Martin
et al., 2009). Furthermore, IGFBP-3 can activate IGF-1R via the
phosphatidylinositol-3 kinase pathway (Conover et al., 2000).
Interestingly, there is evidence supporting IGFBP-3 directly
interacting with IGF-1R (Mohseni-Zadeh & Binoux, 1997). In
addition, it has also been reported that IGFBP-3 independently
mediates TGF-β-induced smoothmuscle cell and carcinoma cell
proliferation (Cohen et al., 2000; Kansra et al., 2000), with
TGF-β known to be stored and released by megakaryocytes
(Fava et al., 1990). Furthermore, IGFBP-3 has been shown to
synergise with Jagged-1 and Delta-1 to increase HSC prolifer-
ation (Liu et al., 2003).
IGFBP-3 and acid-labile subunit are able to sequester
IGF-1 to increase the half-life of IGF-1 from 10 min to 15 h
(Guler et al., 1989; Baxter, 1994). This could account for
the non-significant increase in proliferation when eLSKSLAM
were cultured in IGF-1 alone; without IGFBP-3 to prolong
the activity of IGF-1, eLSKSLAM received no additional signal
to increase their proliferation. However, in the presence of
IGF-1 and IGFBP-3, both IGF-1 direct and indirect mecha-
nisms appear to induce hemopoietic cell proliferation.
Whilst we demonstrate that IGF-1 and IGFBP-3 increase
hemopoietic cell proliferation, we cannot exclude the role of
other IGF and IGFBP family members. For example, IGFBP-2, -4,-5 and -6 in conjunction with, or independent of IGFs may
regulate hemopoietic stem and progenitor cell migration and/
or proliferation (Grellier et al., 1995; Bartling et al., 2010).
Furthermore, endogenous or exogenous IGFBP-2 and IGF-2 have
previously been shown to stimulate HSC proliferation (Zhang &
Lodish, 2004; Huynh et al., 2008, 2011). We now demonstrate
that MM release IGF-2 and IGFBP-2 into the environment and
therefore may potentially regulate HSC via this mechanism.
While, our IGF-1 neutralising antibody ameliorated the
additive IGF-1 and IGFBP-3 induced increase in hemopoietic
cell proliferation in vitro, its ability to modify the actions of
other IGF and IGFBP family members remains unclear.
We report that LSKSLAM cells isolated from the central
BM region do not show significantly increased proliferation
when co-cultured with MM, despite MM being randomly dis-
tributed throughout the marrow and HSC and MM co-localizing
post-transplant. Furthermore, no difference in IGF1-R ex-
pression between LSKSLAM cells isolated from the central
or endosteal region was detected (data not shown). This
difference in effects on HSC isolated from the endosteal versus
central BM regions is consistent with our previously published
work demonstrating that although phenotypically identical for
lineage, Sca-1, c-Kit, CD150 and CD48 expression, stem cells
isolated from different regions of the BM have different
functional potential both in vitro and in vivo (Grassinger et al.,
2010; Haylock et al., 2007). These functional differences are
likely to be due to a combination of intrinsic and other
extrinsic microenvironmental influences. Our data demon-
strates that in the presence of MM, HSC isolated from the
endosteal region retain their natural ability to proliferate
faster than their central counterpart. However, in the presence
of MM, this increased proliferation is amplified because MM
release additional stimulatory signals.
Interestingly, our data showed that when eLSKSLAM
were co-cultured with individual ploidy MM, the significant
increase in proliferation was no longer observed. In addition,
we observed less than expected proliferation when eLSKSLAM
cells were co-cultured with MM that had been stained with
Hoechst33342 (Fig. 3G compared to Fig. 3C). This could be due
to Hoechst33342 interfering withMM induced hemopoietic cell
proliferation as it is known that Hoechst33342 can cause
cytotoxicity and affect cell cycling (Wiezorek, 1984; Erba et
al., 1988). Our experiments revealed that only 32N MM, not 8N
or 16N MM, express IGFBP-3 transcript; while 8N MM express
more IGF-1 transcript than 16N or 32N MM. Therefore, dif-
ferent ploidy populations may contribute differently to affect
eLSKSLAM cell proliferation. However, ELISA data showed that
compared to 32N MM, and despite having no detectable
IGFBP-3 transcript, 16N MM released similar quantities of
IGFBP-3 into culture media. It has previously been shown that
MM endocytose and store IGF-1 and IGFBP-3 in platelet
α-granules (Chan& Spencer, 1998). Aswe very rarely observed
pro-platelet formation and platelets during MM cultures,
release of these cytokines from platelets would not have
impacted on our results. Taken together, it is possible that
32N MM produce endogenous IGFBP-3 as well as endocytose
IGFBP-3 from the environment, and this could account for
the slight but non-significant increase in hemopoietic cell
proliferation while in co-culture with 32N MM. Other factors
may also be involved and therefore, more experimentation is
required to determine any importance of ploidy in hemopoi-
etic cell proliferation.
791Megakaryocytes regulate hemopoietic stem cellsOur hypothesis that MM regulate HSC is also supported by
several other studies. Umbilical cord blood (UCB) differen-
tiated CD41+ megakaryocytes have a stimulatory effect on
UCB stem cells by promoting the proliferation of long-term
culture initiating cells (Kirouac et al., 2010). In addition, MM
produce the known HSC regulator IL-6 (Suzuki et al., 1989;
Jiang et al., 1994). MM also influence HSC indirectly by
regulating OB (via α3β1, α5β1 and CD41), which in turn,
regulate HSC (Lemieux et al., 2010). This is potentially
mediated through GATA-1; because GATA-1 deficient mice
have increased numbers of megakaryocytes as well as
increased bone mass (Ciovacco et al., 2010). MM are a
major source of factors such as thrombospondin, platelet-
derived growth factor, basic fibroblast growth factor-2,
bone morphogenic proteins-2, -4 and -6, receptor activator
for nuclear factor κ B ligand, osteocalcin, osteonectin,
osteopontin, osteoprotegerin and bone sialoprotein, which
are important in the regulation of bone homeostasis, HSC, as
well as recovery of the vasculature and OB following BM
damage (Kacena et al., 2006; Kopp et al., 2006; Dominici et
al., 2009). Therefore, the fact that megakaryocytes secrete
many cytokines that influence the proliferation and survival
of not only HSC and other hemopoietic cell types, but also
bone formation, highlights their key regulatory role and
identifies them as a potential niche component.
In conclusion, our data suggests that MM regulate HSC via
cytokine release. MM are randomly distributed within the
BM, but HSC preferentially lodge within two cells of MM
post-transplant. MM increase hemopoietic cell proliferation
in vitro via the release of IGF-1 and IGFBP-3. This strongly
implicates this mature hemopoietic cell type, primarily
responsible for platelet production, as actively contributing
to HSC regulation by providing signals that not only maintain
and induce stem cell proliferation, but also influence the
make-up of the BM microenvironment.
Authorship contributions
S.H. and S.N. designed and performed experiments, analysed
data and wrote the manuscript. R.N. designed and performed
experiments, analysed data and assessed the manuscript.
B.W. was fundamental in developing prospective MM ploidy
cell separation and performed experiments. D.H. designed
experiments and critically analysed the manuscript. T.A.
provided intellectual input underpinning experimental design,
supplied reagents and critically analysed the manuscript.
Disclosure of conflict of interest
The authors have no conflicts of interest to disclose.
Acknowledgments
This work was supported by grants from the Australian Stem
Cell Centre to S.N. We thank Chad Heazlewood, Andrea
Reitsma and Songhui Li for technical assistance, Daniela
Cardozo for assistance with animal work, Robert Baxter for
intellectual input, Dave Winkler for assistance with statistical
analysis, Peter McCourt for critically assessing themanuscript,
Patrick Tam for RFP mice and Jochen Grassinger for providingimage 1C. We also thank Andrew Fryga, Michael Reitsma,
Kathryn Flanagan and Karen Clarke for flow cytometric
support.
References
Bartling, B., Koch, A., Simm, A., Scheubel, R., Silber, R.E., Santos,
A.N., 2010. Insulin-like growth factor binding proteins-2 and -4
enhance the migration of human CD34−/CD133+ hematopoietic
stem and progenitor cells. Int. J. Mol. Med. 25 (1), 89–96.
Baxter, R.C., 1994. Insulin-like growth factor binding proteins in the
human circulation: a review. Horm. Res. 42 (4–5), 140–144.
Beeton, C.A., Bord, S., Ireland, D., Compston, J.E., 2006. Osteoclast
formation and bone resorption are inhibited by megakaryocytes.
Bone 39 (5), 985–990.
Bord, S., Frith, E., Ireland, D.C., Scott, M.A., Craig, J.I., Compston,
J.E., 2005. Megakaryocytes modulate osteoblast synthesis of
type-l collagen, osteoprotegerin, and RANKL. Bone 36 (5), 812–819.
Chan, K., Spencer, E.M., 1998. Megakaryocytes endocytose insulin-
like growth factor (IGF) I and IGF-binding protein-3: a novel
mechanism directing them into alpha granules of platelets.
Endocrinology 139 (2), 559–565.
Ciovacco, W.A., Cheng, Y.H., Horowitz, M.C., Kacena, M.A., 2010.
Immature and mature megakaryocytes enhance osteoblast
proliferation and inhibit osteoclast formation. J. Cell. Biochem.
109 (4), 774–781.
Cohen, P., Rajah, R., Rosenbloom, J., Herrick, D.J., 2000. IGFBP-3
mediates TGF-beta1-induced cell growth in human airway smooth
muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 278 (3),
L545–L551.
Conover, C.A., Bale, L.K., Durham, S.K., Powell, D.R., 2000. Insulin-
like growth factor (IGF) binding protein-3 potentiation of IGF
action is mediated through the phosphatidylinositol-3-kinase
pathway and is associated with alteration in protein kinase
B/AKT sensitivity. Endocrinology 141 (9), 3098–3103.
Dominici, M., Rasini, V., Bussolari, R., et al., 2009. Restoration and
reversible expansion of the osteoblastic hematopoietic stem cell
niche after marrow radioablation. Blood 114 (11), 2333–2343.
Ellis, S.L., Grassinger, J., Jones, A., et al., 2011. The relationship
between bone, hemopoietic stem cells, and vasculature. Blood
118 (6), 1516–1524.
Erba, E., Ubezio, P., Broggini, M., Ponti, M., D'Incalci, M., 1988. DNA
damage, cytotoxic effect and cell-cycle perturbation of Hoechst
33342 on L1210 cells in vitro. Cytometry 9 (1), 1–6.
Fava, R.A., Casey, T.T., Wilcox, J., Pelton, R.W., Moses, H.L.,
Nanney, L.B., 1990. Synthesis of transforming growth factor-
beta 1 by megakaryocytes and its localization to megakaryocyte
and platelet alpha-granules. Blood 76 (10), 1946–1955.
Ferkowicz, M.J., Starr, M., Xie, X., et al., 2003. CD41 expression
defines the onset of primitive and definitive hematopoiesis in
the murine embryo. Development 130 (18), 4393–4403.
Grassinger, J., Haylock, D.N., Storan, M.J., et al., 2009. Thrombin-
cleaved osteopontin regulates hemopoietic stem and progenitor
cell functions through interactions with alpha9beta1 and
alpha4beta1 integrins. Blood 114 (1), 49–59.
Grassinger, J., Haylock, D.N., Williams, B., Olsen, G.H., Nilsson,
S.K., 2010. Phenotypically identical hemopoietic stem cells
isolated from different regions of bone marrow have different
biologic potential. Blood 116 (17), 3185–3196.
Grellier, P., Yee, D., Gonzalez, M., Abboud, S.L., 1995. Character-
ization of insulin-like growth factor binding proteins (IGFBP) and
regulation of IGFBP-4 in bone marrow stromal cells. Br. J.
Haematol. 90 (2), 249–257.
Guler, H.P., Zapf, J., Schmid, C., Froesch, E.R., 1989. Insulin-like
growth factors I and II in healthy man. Estimations of half-lives
and production rates. Acta Endocrinol. (Copenh) 121 (6),
753–758.
792 S.Y. Heazlewood et al.Haylock, D.N., Williams, B., Johnston, H.M., et al., 2007. Hemopoi-
etic stem cells with higher hemopoietic potential reside at the
bone marrow endosteum. Stem Cells 25 (4), 1062–1069.
Heazlewood, S.Y., Williams, B., Storan, M.J., Nilsson, S.K., 2013.
The prospective isolation of viable, high ploidy megakaryocytes
from adult murine bone marrow by fluorescence activated cell
sorting. In: Turksen, K. (Ed.), Stem Cell Niche: Methods and
Protocols, Methods in Molecular Biology, vol. 1035. Springer
Science + Business Media LLC, USA.
Huynh, H., Iizuka, S., Kaba, M., et al., 2008. Insulin-like growth
factor-binding protein 2 secreted by a tumorigenic cell line
supports ex vivo expansion of mouse hematopoietic stem cells.
Stem Cells 26 (6), 1628–1635.
Huynh, H., Zheng, J., Umikawa, M., et al., 2011. IGF binding protein
2 supports the survival and cycling of hematopoietic stem cells.
Blood 118 (12), 3236–3243.
Jennings, L.K., Phillips, D.R., 1982. Purification of glycoproteins IIb
and III from human platelet plasma membranes and character-
ization of a calcium-dependent glycoprotein IIb–III complex.
J. Biol. Chem. 257 (17), 10458–10466.
Jiang, S., Levine, J.D., Fu, Y., et al., 1994. Cytokine production by
primary bone marrow megakaryocytes. Blood 84 (12), 4151–4156.
Kacena, M.A., Shivdasani, R.A., Wilson, K., et al., 2004.
Megakaryocyte–osteoblast interaction revealed in mice defi-
cient in transcription factors GATA-1 and NF-E2. J. Bone Miner.
Res. 19 (4), 652–660.
Kacena, M.A., Nelson, T., Clough, M.E., et al., 2006. Megakaryocyte-
mediated inhibition of osteoclast development. Bone 39 (5),
991–999.
Kansra, S., Ewton, D.Z., Wang, J., Friedman, E., 2000. IGFBP-3
mediates TGF beta 1 proliferative response in colon cancer cells.
Int. J. Cancer 87 (3), 373–378.
Kirouac, D.C., Ito, C., Csaszar, E., et al., 2010. Dynamic interaction
networks in a hierarchically organized tissue. Mol. Syst. Biol. 6, 417.
Kopp, H.G., Hooper, A.T., Broekman, M.J., et al., 2006.
Thrombospondins deployed by thrombopoietic cells determine
angiogenic switch and extent of revascularization. J. Clin.
Invest. 116 (12), 3277–3291.
Lemieux, J.M., Horowitz, M.C., Kacena, M.A., 2010. Involvement of
integrins alpha(3)beta(1) and alpha(5)beta(1) and glycoprotein
IIb in megakaryocyte-induced osteoblast proliferation. J. Cell.
Biochem. 109 (5), 927–932.
Liu, L.Q., Sposato, M., Liu, H.Y., et al., 2003. Functional cloning of
IGFBP-3 from human microvascular endothelial cells reveals its
novel role in promoting proliferation of primitive CD34 + CD38-
hematopoietic cells in vitro. Oncol. Res. 13 (6–10), 359–371.
Martin, J.L., Baxter, R.C., 2011. Signalling pathways of insulin-like
growth factors (IGFs) and IGF binding protein-3. Growth Factors
29 (6), 235–244.
Martin, J.L., Lin, M.Z., McGowan, E.M., Baxter, R.C., 2009.
Potentiation of growth factor signaling by insulin-like growthfactor-binding protein-3 in breast epithelial cells requires
sphingosine kinase activity. J. Biol. Chem. 284 (38), 25542–25552.
Mohseni-Zadeh, S., Binoux, M., 1997. Insulin-like growth factor (IGF)
binding protein-3 interacts with the type 1 IGF receptor, reducing
the affinity of the receptor for its ligand: an alternativemechanism
in the regulation of IGF action. Endocrinology 138 (12), 5645–5648.
Nakamura-Ishizu, A., Okuno, Y., Omatsu, Y., et al., 2012.
Extracellular matrix protein tenascin-C is required in the bone
marrow microenvironment primed for hematopoietic regenera-
tion. Blood 119 (23), 5429–5437.
Nilsson, S.K., Dooner, M.S., Tiarks, C.Y., Weier, H.U., Quesenberry,
P.J., 1997. Potential and distribution of transplanted hemato-
poietic stem cells in a nonablated mouse model. Blood 89 (11),
4013–4020.
Nilsson, S.K., Haylock, D.N., Johnston, H.M., Occhiodoro, T.,
Brown, T.J., Simmons, P.J., 2003. Hyaluronan is synthesized by
primitive hemopoietic cells, participates in their lodgment at
the endosteum following transplantation, and is involved in the
regulation of their proliferation and differentiation in vitro.
Blood 101 (3), 856–862.
Nilsson, S.K., Johnston, H.M., Whitty, G.A., et al., 2005.
Osteopontin, a key component of the hematopoietic stem cell
niche and regulator of primitive hematopoietic progenitor cells.
Blood 106 (4), 1232–1239.
Schofield, R., 1978. The relationship between the spleen colony-
forming cell and the haemopoietic stem cell. Blood Cells 4 (1–2),
7–25.
Shen, Y., Nilsson, S.K., 2012. Bone, microenvironment and hema-
topoiesis. Curr. Opin. Hematol. 19 (4), 250–255.
Smith, L.H., Clayton, M.L., 1970. Distribution of injected 59Fe in
mice. Exp. Hematol. 20, 82–86.
Stier, S., Ko, Y., Forkert, R., et al., 2005. Osteopontin is a
hematopoietic stem cell niche component that negatively
regulates stem cell pool size. J. Exp. Med. 201 (11), 1781–1791.
Suzuki, C., Okano, A., Takatsuki, F., et al., 1989. Continuous
perfusion with interleukin 6 (IL-6) enhances production of
hematopoietic stem cells (CFU-S). Biochem. Biophys. Res.
Commun. 159 (3), 933–938.
Twigg, S.M., Hardman, K.V., Baxter, R.C., 2000. A purified bovine
serum albumin preparation contains an insulin-like growth factor
(IGF) binding protein-3 fragment that forms ternary complexes
selectively with IGF-II and the acid-labile subunit. Growth Horm.
IGF Res. 10 (4), 215–223.
Wiezorek, C., 1984. Cell cycle dependence of Hoechst 33342 dye
cytotoxicity on sorted living cells. Histochemistry 81 (5), 493–495.
Winter, O., Moser, K., Mohr, E., et al., 2010. Megakaryocytes
constitute a functional component of a plasma cell niche in the
bone marrow. Blood 116 (11), 1867–1875.
Zhang, C.C., Lodish, H.F., 2004. Insulin-like growth factor 2
expressed in a novel fetal liver cell population is a growth factor
for hematopoietic stem cells. Blood 103 (7), 2513–2521.
